NewAmsterdam Pharma Company N.V.
NAMS
ISIN NL00150012L7 / Valor 123483043
NewAmsterdam Pharma Company N.V.
UMushroom community rating:
About company
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm focused on the development of innovative therapies for cardiovascular diseases. The company's lead investigational candidate, obicetrapib, is a selective inhibitor targeting the Cholesteryl Ester Transfer Protein (CETP). Clinical trials have demonstrated that obicetrapib significantly reduces low-density lipoprotein cholesterol (LDL-C) while increasing high-density lipoprotein cholesterol (HDL-C), potentially transforming the ratio of good versus bad cholesterol in the body. This mechanism of action aims to lower the risk of adverse cardiovascular outcomes, as evidenced by previous CETP inhibitors that have shown clinical benefits in large-scale trials. Obicetrapib is distinguished by its improved selectivity, potency, and favorable safety and tolerability profile compared to earlier CETP inhibitors.
Summarized from source with an LLMView SourceSector: FinanceKey figures
Performance
Volatility
2979 M
Market cap (USD)
714,358
Daily traded volume (Shares)
26.1 / 25.3
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Damien Tan
EQUITIES OF THE SAME SECTOR
